Autologous hematopoietic stem cell transplant is linked to less disability and lower relapse rates than other disease-modifying therapies for patients with secondary progressive multiple sclerosis.
Patients with mantle cell lymphoma (MCL) who survive 2 years without disease recurrence or progression live nearly as long as age- and sex-matched individuals in the general population.